Skip to main content

Table 4 Association of APOE polymorphism with the risk of T2DM, CVD, T2DM + CVD+

From: Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes

Genotype Control (n = 211) T2DM (n = 247) Unadjusted OR (95% CI) CVD (n = 232) Unadjusted OR (95% CI) T2DM + CVD+ (n = 234) Unadjusted OR (95% CI)
E3/E3 160 183 0.91 (0.60–1.39) 144 0.51 (0.34–0.77)** 139 0.47 (0.31–0.70)**
E2/E3 24 16 0.54 (0.28–1.05) 23 0.86 (0.47–1.57) 20 0.73 (0.39–1.36)
E3/E4 25 43 1.57 (0.92–2.66) 46 1.84(1.09–3.12)* 63 2.74(1.65–4.55)**
ε2 26 20 0.64 (0.35–1.17) 37 0.86 (0.47–1.56) 29 1.02 (0.58–1.74)
ε3 369 425 0.89 (0.60–1.30) 357 0.48 (0.33–0.69)** 361 0.49 (0.34–0.70)**
ε4 26 46 1.56 (0.95–2.57) 70 2.71 (1.69–4.34)** 78 3.05 (1.91–4.85)**
  1. *p-value: all the comparisons were made between patients and controls